Gaize is mastering the art of cannabis impairment detection. The Missoula, Montana-based company is gearing up for the launch of its first science-backed real-time cannabis impairment detection device. Not only this, but Gaize recently completed the largest clinical trial into cannabis impairment, and the results are set to transform the realm of workplace and road safety.
Studies on cannabis have shown that the plant may cause disorientation, sedation, lack of concentration, and impaired judgment. Of course, this depends on a person’s level of tolerance, and while typical THC tests may only scratch the surface in terms of detecting impairment, Gaize has hit the nail on the head.
A study by the National Institute on Drug Abuse learned that 55% more industrial accidents, 75% greater absenteeism, and 85% more injuries occurred among employees who tested positive for marijuana than those who tested negative. A separate study published in Frontiers in Psychiatry found that consumption increased the risk of traffic crashes by 50%.
Fortunately, Gaize is doing final tuning on its product—a portable and non-invasive testing device that scans the eyes to determine cannabis impairment. Embedded with eye-tracking sensors, the Gaize device is a specialized virtual reality (VR) headset that carries out a series of automated ocular motion and pupillary reflex tests while capturing high-resolution eye movement data and video. It is expected to be launched before the year is up.
To read more, click on Medical Cannabis